COST OF HYPERTENSION MANAGEMENT AMONG PEOPLE LIVING WITH HYPERTENSION IN SELECTED PUBLIC HOSPITALS IN ILORIN, NIGERIA
Author(s)
Felicia E. Williams, MBA, MCom, PharmD, PhD1, Remilekun Ojurongbe, PharmD in view2;
1University of Ilorin, Ilorin, Nigeria, Clinical and Public Health Pharmacist/Lecturer, Ilorin, Nigeria, 2University of Ilorin, Ilorin, Nigeria, Clinical Pharmacy and Pharmacy practice, Ilorin, Nigeria
1University of Ilorin, Ilorin, Nigeria, Clinical and Public Health Pharmacist/Lecturer, Ilorin, Nigeria, 2University of Ilorin, Ilorin, Nigeria, Clinical Pharmacy and Pharmacy practice, Ilorin, Nigeria
OBJECTIVES: Cost of hypertension management (HM) constitute substantial financial strain on individuals and households. There is dearth of information on cost of HM among people living with hypertension (PLHT) Ilorin. This study assessed the cost of HM among PLHT at selected hospitals in Ilorin, Nigeria.
METHODS: A multi-centre cross-sectional study was conducted in three selected public hospitals that provided healthcare to PLHT in Ilorin. Systematic random sampling was used to recruit 166 eligible PLHT (based on Fisher's formula). Demographic, clinical, treatment and financial data were collected using pretested structured questionnaire adapted from previous studies. Data were analyzed using descriptive and inferential statistics (Chi-Square and Kruskal-Wallisi tests) with significance level set at p < 0.05.
RESULTS: Of the 166 PLHT, 68.7% were females, median age was 60.5 years (interquartile range [IQR] = 70 - 50 years), 83.7% were married, and 23.5% were enrolled in health insurance schemes (HISs). Anti-hypertensives used by 34.3%, 31.3% and 15.7% of PLHT were amilodipine, amilodipine/telmisartan, and amilodipine/termisartan/hydroclorthiazide respectively. Median monthly cost of HM per patient (HM/P) was NGN 8100 ([USD 5.59]; [IQR = NGN 12062.5 - 5775.0; USD 8.3 - 4.0]). Median monthly direct medical (DM) and direct non-medical (DN) costs of HM/P were NGN 6200 ([USD 4.3]; [IQR = NGN 9132.5 - 3915.0; USD 6.3-2.7]) and NGN 1000 ([USD 0.7]; [IQR = NGN 2000 - 600; USD 1.4 - 0.4]) respectively. Contribution of DM cost to total costs of HM/P was 75.4%. Significant differences were observed between median DM cost (p < 0.001) and DN cost (p = 0.023) across the three health facilities.
CONCLUSIONS: Enrollment of PLHT in HISs was low. Direct medical cost had highest component of the total cost of illness. This study recommends that PLHT should be enrolled in HISs. This will greatly reduce the cost of illness of hypertension.
METHODS: A multi-centre cross-sectional study was conducted in three selected public hospitals that provided healthcare to PLHT in Ilorin. Systematic random sampling was used to recruit 166 eligible PLHT (based on Fisher's formula). Demographic, clinical, treatment and financial data were collected using pretested structured questionnaire adapted from previous studies. Data were analyzed using descriptive and inferential statistics (Chi-Square and Kruskal-Wallisi tests) with significance level set at p < 0.05.
RESULTS: Of the 166 PLHT, 68.7% were females, median age was 60.5 years (interquartile range [IQR] = 70 - 50 years), 83.7% were married, and 23.5% were enrolled in health insurance schemes (HISs). Anti-hypertensives used by 34.3%, 31.3% and 15.7% of PLHT were amilodipine, amilodipine/telmisartan, and amilodipine/termisartan/hydroclorthiazide respectively. Median monthly cost of HM per patient (HM/P) was NGN 8100 ([USD 5.59]; [IQR = NGN 12062.5 - 5775.0; USD 8.3 - 4.0]). Median monthly direct medical (DM) and direct non-medical (DN) costs of HM/P were NGN 6200 ([USD 4.3]; [IQR = NGN 9132.5 - 3915.0; USD 6.3-2.7]) and NGN 1000 ([USD 0.7]; [IQR = NGN 2000 - 600; USD 1.4 - 0.4]) respectively. Contribution of DM cost to total costs of HM/P was 75.4%. Significant differences were observed between median DM cost (p < 0.001) and DN cost (p = 0.023) across the three health facilities.
CONCLUSIONS: Enrollment of PLHT in HISs was low. Direct medical cost had highest component of the total cost of illness. This study recommends that PLHT should be enrolled in HISs. This will greatly reduce the cost of illness of hypertension.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE3
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)